Expression and distribution of galanin receptor subtypes in the rat carotid body

ANDREA PORZIONATO1, VERONICA MACCHI1, LUISA BARZON2, GIULIA MASI2, ANNA BELLONI1, ANNA PARENTI3, GIORGIO PALÙ2 and RAFFAELE DE CARO1

Department of 1Human Anatomy and Physiology, Section of Anatomy; 2Department of Histology, Microbiology and Medical Biotechnologies; 3Department of Medical Diagnostic Science and Special Therapies, Section of Pathologic Anatomy, University of Padua, I-35121 Padua, Italy

Received August 3, 2009; Accepted September 21, 2009

DOI: 10.3892/mmr_00000215

Abstract. Galanin is a 29 amino acid neuropeptide that is widely distributed in the nervous system and acts by binding to three G protein-coupled receptors (GalR1, GalR2 and GalR3). In the literature, the presence of galanin has been reported in nerve fibers innervating the rat carotid body; however, direct evidence of the different galanin receptor subtypes expressed in carotid body cells has yet to be provided. In the present study, we investigated the presence and location of the three galanin receptor subtypes in 12 rat carotid bodies through real-time polymerase chain reaction (PCR) and immunohistochemistry. Real-time PCR identified GalR1 and GalR2 mRNA, with GalR2 gene expression being 100 times higher than that of the GalR1 gene. GalR3 mRNA was not detected. Statistically significant differences were not observed between the mean number of GalR1- and GalR2-positive type I cells (40.5±15.5 vs. 37.1±13.2%). Anti-GalR3 immunohistochemistry did not identify positive cells in the carotid body. Type II cells were negative for the three galanin receptor subtypes. Our findings suggest that galanin may play a neuromodulator or trophic role in type I cells by binding to GalR1 and GalR2.

Introduction

Galanin is a 29 amino acid neuropeptide initially isolated from porcine intestine (1) and widely distributed in the central and peripheral nervous system. Galanin has been found to regulate many different functions in the central nervous system, such as energy and osmotic homeostasis, arousal/sleep regulation, reproduction, nociception and cognition.
total rna was isolated from sections were incubated for immediately on dry ice and stored at -80˚c. surrounding tissues under a dissecting microscope, frozen were dissected and the carotid bodies were cleaned from the processing. for real-time pcr, left carotid bifurcations were cut on a cryostat, mounted directly onto silane-coated in liquid nitrogen-cooled isopentane. thick sections of 5 µm then embedded in ocT compound and frozen by immersion maintained in 30% sucrose overnight at 4˚c. samples were sampled, fixed in 4% paraformaldehyde for 1 h, and then for immunohistochemistry, right carotid bifurcations in 200-250 g. Sampling of rats was performed soon after sacri bodies obtained from 12 adult sprague-dawley rats weighing tissue sampling and preparation.

**Materials and methods**

**Tissue sampling and preparation.** Materials consisted of carotid bodies obtained from 12 adult sprague-dawley rats weighing 200-250 g. Sampling of rats was performed soon after sacrifice. For immunohistochemistry, right carotid bifurcations were sampled, fixed in 4% paraformaldehyde for 1 h, and then maintained in 30% sucrose overnight at 4˚c. Samples were then embedded in OCT compound and frozen by immersion in liquid nitrogen-cooled isopentane. Thick sections of 5 µm were cut on a cryostat, mounted directly onto silane-coated slides, and maintained at -80˚c until immunohistochemical processing. For real-time pcr, left carotid bifurcations were dissected and the carotid bodies were cleaned from the surrounding tissues under a dissecting microscope, frozen immediately on dry ice and stored at -80˚c.

**Real-time PCR analysis.** Total RNA was isolated from tissue samples using an RNeasy extraction kit (Qiagen GmbH, Hilden, Germany). RNA was subjected to two treatments with DNA-free (Applied Biosystems/Ambion Austin, TX, USA) in order to remove any genomic DNA contamination, and random primed cDNAs were generated from 3 µg of total RNA using MuLV reverse transcriptase (Applied Biosystems, Foster City, CA, USA). Quantitative real-time RT-PCR for genes encoding for β-actin and galanin receptors was performed using primers and probes designed with ProbeFinder for the Universal ProbeLibrary Set (Roche Diagnostics SpA, Monza, MI, Italy) (Table I). PCR amplifications were performed in duplicate under standard conditions using an ABI PRISM 7700 Sequence Detector System (Applied Biosystems). Relative quantification of transcripts was performed using the comparative 2-ΔΔCT (threshold cycle) method (29).

**Immunohistochemical analysis.** Sections were incubated for 10 min with 0.01 M phosphate buffer saline (PBS) containing 0.1% Triton® X-100. Unmasking was performed with 10 mM sodium citrate buffer, pH 6.0, in a microwave oven at 900 watts. Primary antibody incubations were performed as follows: anti-GalR1 [goat polyclonal anti-GalR1 (C-20) sc-16216; Santa Cruz Biotechnology Inc., CA, USA] diluted 1:100 in blocking serum; anti-GalR2 [goat polyclonal anti-GalR2 (K-20) sc-16216; Santa Cruz Biotechnology Inc., CA, USA] diluted 1:50 in blocking serum; anti-GalR3 [goat polyclonal anti-GalR3 (L-20) sc-16416; Santa Cruz Biotechnology Inc., CA, USA] diluted 1:50 in blocking serum. Sections were then washed three times for 5 min in PBS, revealed with anti-goat serum (Vectastain Elite ABC kit Goat IgG PK-6105; Vector Laboratories Inc., Burlingame, CA, USA) for 30 min at room temperature and developed in 3,3'-diaminobenzidine (DAB; Sigma-Aldrich, Milan, Italy). Lastly, the sections were counterstained with hematoxylin. Negative controls were performed by the omission of primary antibody and through absorption tests. GalR immunoreactions detected in rat brain were used as positive controls.

The percentage of type I and II GalR-positive cells was evaluated at a magnification of 40x. Five sections and 3 fields per section were examined. The mean percentage of positive type I and II cells was calculated for each case and for the entire series.

<table>
<thead>
<tr>
<th>Gene</th>
<th>UPL Probe number</th>
<th>Primers</th>
<th>Amplicon length (nt)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actb</td>
<td>63</td>
<td>F: ctgetctagccagcatga</td>
<td>76</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R: tagagccaccaactcaca</td>
<td></td>
</tr>
<tr>
<td>GalR1</td>
<td>46</td>
<td>F: tcagaggcatcgaagaagaag</td>
<td>104</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R: aactagccagagggtgaga</td>
<td></td>
</tr>
<tr>
<td>GalR2</td>
<td>71</td>
<td>F: tccacctgggtgataccatgaat</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R: tctgctgctgtcctcc</td>
<td></td>
</tr>
<tr>
<td>GalR3</td>
<td>38</td>
<td>F: ctaactcggcgcgcattac</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R: gactgcatcacaagag</td>
<td></td>
</tr>
</tbody>
</table>

Galanin has been identified by immunohistochemistry in the nerve fibers of rat and chicken carotid bodies (20-27). In chicken carotid bodies, galanin-immunoreactive fibres have mainly been found to derive from the i4th cervical sympathetic ganglion. A portion of galanin-immunoreactive fibres have also been suggested to arise from intrinsic parasympathetic neurons (21-24). In the rat carotid body, most galanin-immunoreactive fibres are sensitive terminals originating from the petrosal ganglion (20,25-27). After transection of the carotid sinus nerve, the disappearance of galanin-immunoreactive nerve fibers and the acquisition of galanin immunoreactivity in originally immunonegative glomic cells and nerve fibers has been reported, probably originating from the superior cervical ganglion (25). In monkey and guinea-pig carotid bodies, galanin immunoreactivity has also been found in type I cells (28). To the best of our knowledge, the presence of the different galanin receptors has not yet been studied in carotid body structures. Thus, the aim of the present study was to investigate, through immunohistochemistry and real-time RT-PCR, the relative expression and distribution of the three galanin receptor subtypes in the rat carotid body, with particular reference to the different cellular populations.

**Materials and methods**

**Tissue sampling and preparation.** Materials consisted of carotid bodies obtained from 12 adult sprague-dawley rats weighing 200-250 g. Sampling of rats was performed soon after sacrifice. For immunohistochemistry, right carotid bifurcations were sampled, fixed in 4% paraformaldehyde for 1 h, and then maintained in 30% sucrose overnight at 4˚c. Samples were then embedded in OCT compound and frozen by immersion in liquid nitrogen-cooled isopentane. Thick sections of 5 µm were cut on a cryostat, mounted directly onto silane-coated slides, and maintained at -80˚c until immunohistochemical processing. For real-time PCR, left carotid bifurcations were dissected and the carotid bodies were cleaned from the surrounding tissues under a dissecting microscope, frozen immediately on dry ice and stored at -80˚c.

**Real-time PCR analysis.** Total RNA was isolated from tissue samples using an RNeasy extraction kit (Qiagen GmbH, Hilden, Germany). RNA was subjected to two treatments with DNA-free (Applied Biosystems/Ambion Austin, TX, USA) in order to remove any genomic DNA contamination, and random primed cDNAs were generated from 3 µg of total RNA using MuLV reverse transcriptase (Applied Biosystems, Foster City, CA, USA). Quantitative real-time RT-PCR for genes encoding for β-actin and galanin receptors was performed using primers and probes designed with ProbeFinder for the Universal ProbeLibrary Set (Roche Diagnostics SpA, Monza, MI, Italy) (Table I). PCR amplifications were performed in duplicate under standard conditions using an ABI PRISM 7700 Sequence Detector System (Applied Biosystems). Relative quantification of transcripts was performed using the comparative 2-ΔΔCT (threshold cycle) method (29).

**Immunohistochemical analysis.** Sections were incubated for 10 min with 0.01 M phosphate buffer saline (PBS) containing 0.1% Triton® X-100. Unmasking was performed with 10 mM sodium citrate buffer, pH 6.0, in a microwave oven at 900 watts. Primary antibody incubations were performed as follows: anti-GalR1 [goat polyclonal anti-GalR1 (C-20) sc-16216; Santa Cruz Biotechnology Inc., CA, USA] diluted 1:100 in blocking serum; anti-GalR2 [goat polyclonal anti-GalR2 (K-20) sc-16216; Santa Cruz Biotechnology Inc., CA, USA] diluted 1:50 in blocking serum; anti-GalR3 [goat polyclonal anti-GalR3 (L-20) sc-16416; Santa Cruz Biotechnology Inc., CA, USA] diluted 1:50 in blocking serum. Sections were then washed three times for 5 min in PBS, revealed with anti-goat serum (Vectastain Elite ABC kit Goat IgG PK-6105; Vector Laboratories Inc., Burlingame, CA, USA) for 30 min at room temperature and developed in 3,3'-diaminobenzidine (DAB; Sigma-Aldrich, Milan, Italy). Lastly, the sections were counterstained with hematoxylin. Negative controls were performed by the omission of primary antibody and through absorption tests. GalR immunoreactions detected in rat brain were used as positive controls.

The percentage of type I and II GalR-positive cells was evaluated at a magnification of 40x. Five sections and 3 fields per section were examined. The mean percentage of positive type I and II cells was calculated for each case and for the entire series.
Statistical analysis. Percentages obtained were compared using the Kruskal-Wallis test and Dunn's multiple comparison test. A P-value of 0.05 was considered significant.

Results

Immunohistochemistry revealed the presence of GalR1- and GalR2-positive type I cells, whereas all type I cells were negative for GalR3 immunostaining. Statistically significant differences were not found between the mean number of GalR1- and GalR2-positive type I cells (40.5±15.5 vs. 37.1±13.2%). Immunostained cells were distributed in the centre and the periphery of the lobules. No GalR1, GalR2 or GalR3 immunostaining was observed in type II cells (Fig. 1). Glomic cell immunostainings were eliminated when pre-absorbed antiserum was used or when primary antibodies were omitted.

Discussion

In the carotid body, glomic type I cells and sensitive and autonomic nerve fibres release numerous neurotransmitters and peptide neuromodulators, which play a role in the regulation of chemoreceptor discharge (15-18,30,31). Circulating factors have also been reported to act on carotid body type I cells. For many of these neuromodulators, the specific receptor types expressed in type I cells are as yet unknown. To the best of our knowledge, this is the first study addressing the expression of galanin receptor types in type I cells. GalR1 and GalR2 were

Figure 1. Immunohistochemistry for anti-GalR1 (A and B), anti-GalR2 (C and D) and anti-GalR3 (E and F) showing immunopositive type I cells (arrows) for GalR1 and GalR2, and negativity for GalR3. Negative controls not shown. Scale bars, 24 µm.
found to be expressed in type I cells using real-time PCR and immunohistochemistry. Immunohistochemistry did not reveal statistically significant differences between the percentage of GalR1- and GalR2-positive type I cells, whereas real-time PCR showed that GalR2 gene expression was approximately 100 times higher than that of the GalR1 gene. Such differences in the results obtained using the two methods may be due to the post-transcriptional regulatory mechanisms of protein synthesis or to the insufficient capability of immunohistochemistry to detect differences in the degree of receptor expression. Conversely, both immunohistochemistry and real-time PCR consistently failed to detect GalR3 expression. Our findings suggest that galanin plays different modulatory roles on chemosensation by type I cells through two different receptors, GalR1 and GalR2. Regulation of the release of neurotransmitters and neuromodulators by galanin has previously been observed in the central and peripheral nervous systems (32,33), and such action may also be hypothesized with regard to carotid body type I cells. Moreover, the binding of galanin to GalR1 and GalR2 is known to stimulate the phosphorylation of ERK and AKT (7), two signalling pathways known to be activated in the carotid body (34).

It is probable that galanin receptors in type I cells preferentially bind galanin that has been locally released in the carotid body. However, circulating blood galanin and GALP are also likely to modulate carotid body function by binding to GalR1 and GalR2. Galanin and GALP are involved in feeding and metabolism regulation. For example, GalR1-KO mice have been reported to exhibit impaired adaptation to an acute 3-day high-fat challenge, with increased food intake and weight gain (35). In mice, acute intracerebroventricular GALP infusion induces a decrease in food intake and body weight, and chronic GALP treatment produces a sustained decrease in body weight, although with the recovery of food intake (36).

Evidence suggests that the effects of galanin and GALP on food intake and metabolism are mainly exerted via central actions in the hypothalamus (7). However, the idea that galanin and GALP could also peripherally modulate metabolism and feeding by binding to GalR1 and GalR2 in glomic type I cells is intriguing. In fact, the carotid body is also considered to play a role in glucose sensing and regulation (37–40), and chronic GALP treatment produces a sustained decrease in body weight, although with the recovery of food intake (36).

Our findings suggest that galanin shows antiproliferative effects on cultured neural stem cells and PC12 cell lines, while in GalR2/3, respectively, galanin shows proliferative action (46,47). Galanin has also been demonstrated to modulate plasticity mechanisms in hippocampal CA1 neurons through the reduction of long-term potentiation (49). In the pre- and post-natal periods, the carotid body undergoes structural changes mediated by trophic factors. These include carotid body volume increase, the proliferation of type I, type II, endothelial and Schwann cells lining the peripheral nerve fibers, and an increased number of synapses between type I and II cells (18,49). Environmental stimuli (for instance, hypoxic, hyperoxic or inflammatory noxae) may also cause a series of morphological, cellular and biochemical changes (18,50,51). For instance, chronic hypoxia has been shown to increase O2 sensitivity in the carotid body through changes in molecular chemoreceptors, ion channels and neurochemicals (reviewed in refs. 52,53). The above changes are mediated by a wide series of trophic factors, and the presence of GalR1 and GalR2 on type I cells in addition to the ascertained role of galanin in cell survival and proliferation suggests a possible role for galanin in and of itself.

Acknowledgements

The authors are grateful to Gloria Sarasin and Anna Rambaldo for skillful technical assistance.

References


